By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; ...
May 25 2016 - 8:30AM
InvestorsHub NewsWire
By
2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With
Predictions 2016 Will Be the Greenest Year in
History;
Company Executes International License
Agreement
Coral Springs, FL -- May 25,
2016 -- InvestorsHub NewsWire -- As illustrated by the Spring
2016 Marijuana Business Conference & Expo earlier this month,
the numbers and momentum of cannabis in the US are undeniable. As
revenues continue to climb into the billions, more research and
development push the sector forward. According to the newly released
4th Edition State of Legal Marijuana Markets
Report from from ArcView Market
Research and New Frontier, a cannabis-focused data-analysis firm,
much of the increase in sector is attributed to adult use market
sales, which hit $1.3 billion last year alone. By 2020, adult use
and medical marijuana sales are expected to reach nearly $23
billion.
In breaking marijuana products
& license advancements in the markets
today:
Freedom Leaf, Inc. (OTC:
FRLF) is proud to announce the international expansion of its
print and multimedia platform, as well as its portfolio of products
and services in the Netherlands. Freedom Leaf, Inc. has
entered into an International License Agreement secured by a
$25,000 non-refundable deposit for the exclusive license to use the
Freedom Leaf Brand with the right to publish the Freedom Leaf
magazine in Dutch offering Advertising, while also undertaking
Public Relations, Business Consulting, Branding Services, Business
Development and Incubation for the Cannabis companies in the
Netherlands. Freedom Leaf, Netherlands will also distribute branded
products and services and will identify emerging opportunities to
bring under the Freedom Leaf umbrella in the US and the
Netherlands.
Read the full Freedom Leaf
(FRLF)
Press Release http://www.financialnewsmedia.com/profiles/frlf.html
Mr. Mario Louis Sylvester Lap is
the Managing member of Freedom Leaf, Netherlands, bv. Mr Lap is a
graduate from Open Universiteit Nederland, BS, Law and currently
has affiliations with the following organizations: Drugtext
Foundation, Foundation on Drug Policy and Human Rights & MLS
LAP bv, RJM and MJR Holding Companies. 45 year
Marijuana Legalization Activist and Freedom Leaf co-founder. Mr
Richard C Cowan speaks about his relationship, "I have known Mario
Lap for over twenty years, and there is no one in Europe who knows
the drug reform world better than Mario."
In other Legal Marijuana /
Cannabis / Cannabidol News and Developments in the
markets: Insys Therapeutics, Inc. (NASDAQ:
INSY) announced that it has successfully completed its Phase
1/Phase 2 safety and pharmacokinetic (PK) study in pediatric
subjects with treatment-resistant epilepsy. In this trial, 61
subjects with refractory epilepsy, between the ages of 1 year to 17
years, received treatment with Insys’ pharmaceutical cannabidiol
(CBD) oral solution across multiple investigative sites in the
United States. The clinical trial evaluated multiple
ascending doses of Insys’ CBD with three cohorts of subjects
receiving total daily doses of 10 mg/kg, 20 mg/kg or 40
mg/kg. Over 80% of these subjects continue to receive CBD in
an ongoing long-term safety study.
84% support medical marijuana - If
you thought full legalization support was high, you haven't seen
anything yet. Based on a CBS News poll conducted in April 2015, 84%
of those surveyed wanted to see marijuana legalized for medicinal
use nationwide. It's not hard to understand why, either, with
companies like GW
Pharmaceuticals (NASDAQ:
GWPH) showcasing the many uses of cannabinoids in early- and
mid-stage clinical trials. For instance, GW Pharmaceuticals'
Epidiolex helped reduced seizure frequency by more than 50% in two
midstage studies for childhood-onset epilepsy in Dravet syndrome
and Lennox-Gastaut syndrome. Read the full Article
at http://www.fool.com/investing/general/2016/05/22/9-fast-facts-about-marijuana-including-1-telling-s.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
Terra Tech
Corp. (OTC:
TRTC), recently announced that its subsidiary, Edible Garden, a
retail seller of locally grown hydroponic produce, herbs, and
floral products, has shipped its first order of
nutritionally-enhanced lettuce to ShopRite Supermarkets. The
lettuce was developed in partnership with Nutrasorb LLC under the
name SUPERLEAF™, in conjunction with Rutgers University, and is the
latest addition to Edible Garden's product line of non-GMO fruits
and vegetables.
Medical Marijuana,
Inc. (OTC:
MJNA) is pleased to announce that its hemp biotech investment,
AXIM Biotechnologies, Inc. (AXIM), has begun the world's first
human dermatological clinical trials on psoriasis (PsO) and atopic
dermatitis (AD) commonly known as eczema based on AXIM's AX-1602
proprietary, patent-pending topical ointment formulation containing
cannabigerol (CBG) and other cannabinoids. Conducting the clinical
trials is a world-renowned dermatologist and specialist on
psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The
Maurits Clinics in The Hague, The Netherlands. Psoriasis and eczema
are estimated to affect nearly 200 million people worldwide by 2024
with combined market estimates at $16 billion by
2022.
FinancialNewsMedia.com is leading
provider of third party publishing & news dissemination
services. If you would like more information regarding our
news coverage solutions, please
visit financialnewsmedia.com for more details. Get
an edge on the market with our Premium News Alerts that are FREE
for a limited time at financialnewsmedia.com. Follow us
on Facebook: facebook.com/financialnewsmedia and
Twitter: twitter.com/FNMgroup.
DISCLAIMER: FN
Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic
information through multiple online media channels. FNMG is
NOT affiliated in any manner with any company mentioned
herein. FNMG and its affiliated companies are a news
dissemination solutions provider and are NOT a registered
broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's
market updates, news alerts and corporate profiles are NOT a
solicitation or recommendation to buy, sell or hold
securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to
perform research and due diligence on their own and consult a
licensed financial professional before considering any level of
investing in stocks. All material included herein is
republished content and details which were previously disseminated
by the companies mentioned in this release. FNMG is not
liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all
or a portion of their investment when investing in stocks.
For current services performed FNMG has been compensated three
thousand five hundred dollars for news coverage of the current
press release issued by Freedom Leaf, Inc. by a non-affiliated
third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN
THIS RELEASE.
This release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans,
results, or strategies and are generally preceded by words such as
"may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and FNMG undertakes no
obligation to update such statements.
Contact
Information:
Company: FN
Media Group, LLC
Contact
email: editor@financialnewsmedia.com
U.S. Phone:
(954)345-0611
URL: www.financialnewsmedia.com
Source: FN Media
Group
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024